Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake off the generic-related declines that have plagued revenues in recent | Takeda's multiyear slim-down is expected to hit about 4,500 roles during the 2026 fiscal year, resulting in about 170 billion Japanese yen ($1.07 billion) in restructuring costs and some 100 billion yen ($633 million) in gross savings for 2026.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Takeda to target 4,500 jobs as incoming CEO continues restructuring

Pharmaceutical Takeda to cut 4,500 from global workforce

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Weiterer Schlag für die Schweizer Pharmaindustrie: Takeda streicht bis zu 280 Stellen

Takeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring.

Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen…

Teva Pharmaceuticals plans to remove 250 jobs at its CDMO unit over the next two years, Israeli business news outlet Globes

Japanese pharmaceutical Takeda has announced layoffs affecting 4,500 people from its global workforce, which may impact employees…

With China's growing dominance in the biopharma R&D sector, a collection of g | A group of over 20 global pharma leaders met with…